Attendee search 

Cynvenio has developed a new LiquidBiopsy technology to sequence the DNA of tumor cells isolated from peripheral blood. Key applications include longitudinal patient monitoring throughout the cancer care cycle, the detection of resistance mutations, and providing physicians with accurate molecular evidence to select the best targeted therapy for a given patient.

Cynvenio's technology can be accessed as a CLIA lab service, or  can be installed and operated inside hospital labs and cancer research centers. Cynvenio's lab has been CLIA certified since 2013 and LiquidBiopsy system deployments began in the second half of 2014.

The HudsonAlpha Institute for Biotechnology

The HudsonAlpha Institute for Biotechnology is a Genomic focused Institute located on a 152-acre bio-medical research campus in Huntsville, Alabama whose mission is to translate scientific breakthroughs in the laboratory into real-world benefits that have a profound impact on people’s lives.

HudsonAlpha BioVentures Philanthropic Fund

•       Specific Philanthropic Fund - part of the HudsonAlpha Foundation a tax-exempt, 501(c) 3 non-profit organization.

•       All investments to the Fund are tax-deductible

•       Fund goal is $50 million

•       Targeted toward donors seeking to make a long-term impact in human health and make a difference for thousands, even millions, of people suffering from serious disease.

Option 1

HudsonAlpha Foundation invests funds in new or established companies and scientific discoveries. Foundation will have an equity stake and receive a ROI, as companies are successful. The return is reinvested into other companies and HudsonAlpha to further its mission and goals – the multiplier effect.

Option 2

HudsonAlpha Foundation will fund promising intellectual property emanating from HudsonAlpha laboratories.

Option 3

HudsonAlpha Foundation provides grant funding to companies who are relocating to or expanding on the HudsonAlpha campus.

All investors/donors will have an opportunity to invest in the future in any and all companies and will be informed regularly on the progress of these companies

Small biotechnology companies are developing half of all future medicines, some of which may not reach patients due to lack of funding from traditional investors.

Although health-related charities received more than $31B in contributions in 2013, many of the charities which support research do not work with for-profit biotech companies. They predominantly fund academic and non-profit institutions which typically conduct early research and discover around 10% of new medicines (for-profit companies discover the remaining 90%).

Impatient is a new kind of health-related charity. We will only fund medical trials with small biotech companies.  

Our scientific advisors will select promising, unfunded, medical treatments. You choose which treatment to support and 100% of your donation is spent on testing.

If the treatment is successful, 100% of the future royalty that Impatient receives from the biotech company will support access to new medicines for people who cannot afford them.  

Torrey Pines Investment (TPI) was founded in 22 and is based in San Diego CA. The firm has raised two funds and also invests in drug development via a partnership with BioMotiv. TPI makes venture-stage minority equity investments and prefers act as a co-investor but also leads rounds on occasion. The firm invests internationally.

Life Sciences Alternative Funding (LSAF) founded in 213 is a direct investment firm based in White Plains New York. The firm focuses exclusively on providing debt capital for commercial-stage medical technology companies. The firm can allocate between USD 1M-5M per investment. The firm looks to provide flexible ?tailor-made? financing solution to companies. The firm can invest globally and is currently seeking new investment opportunities.

Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.